Episode summary introduction:
The term PH means high blood pressure in the lungs. This is not to be confused with “regular” systemic hypertension -that can be measured with a blood pressure cuff. In PH, the blood vessels specifically in the lungs are affected. They can become stiff, narrow and even damaged. This makes the right side of the heart work harder to pump blood through the lungs.
In this section we discuss statistics of pulm. HTN, the signs and systems, and risk factors that are associated with this disease process.
Who groupings classifications are discussed.
The diagnosis of PAH is one of exclusion. Meaning that PAH is only diagnosed when other causes of pulmonary hypertension have been ruled out. Diagnostic testing is discussed.
Treatments are discussed such as; Prostacyclin signaling is a major pathway in the pathophysiology of PAH. The prostacyclin synthase and its metabolites are reduced in PAH patients. Prostacyclin is mostly produced by endothelial cells. The endothelin pathway. Phosphodiesterase type 5 inhibitors. Non-Specific PH Medications, calcium channel blockers.
Raising awareness around this rare disease is key to patients being diagnosed sooner and being treated faster. We need to work hard to lower the average, of 2 years, to being diagnosed. And like with anything in medicine, the sooner the treatment begins, the better the outcomes for our patients.